PTC Therapeutics (NASDAQ:PTCT) Stock Rating Reaffirmed by Cantor Fitzgerald

PTC Therapeutics (NASDAQ:PTCT – Get Rating)‘s stock had its “overweight” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a report issued on Friday, Zacks.com reports. Other analysts also recently issued research reports about the stock. JPMorgan Chase & Co. increased their target price on shares of PTC Therapeutics from $70.00 to $76.00 and […]

Related Keywords

Hong Kong ,Neil Gregory Almstead ,Therapeutics Company Profile Get Rating ,Zacks Investment Research ,Meeder Asset Management Inc ,Nisa Investment Advisors ,Jpmorgan Chase Co ,Cantor Fitzgerald ,Therapeutics Inc ,First Mercantile Trust Co ,Raymond James Associates ,Barclays ,Hong Kong Ltd ,Get Rating ,Marie Utter ,Asset Management ,Mercantile Trust ,Kong Ltd ,Investment Advisors ,Raymond James ,Company Profile ,Ptc Therapeutics ,Nasdaq Ptct ,Ptct ,Medical ,Reiterated Rating ,